APA (7th ed.) Citation

H, F., J, P., C, M., D, P., G, K., MB, A., & T, F. (2018). Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer. Medical oncology (Northwood, London, England), 35(3), 32. https://doi.org/10.1007/s12032-018-1087-6

Chicago Style (17th ed.) Citation

H, Fuchs, Pammer J, Minichsdorfer C, Posch D, Kornek G, Aretin MB, and Fuereder T. "Modified Biweekly Cisplatin, Docetaxel Plus Cetuximab (TPEx) as First-line Treatment for Patients with Recurrent/metastatic Head and Neck Cancer." Medical Oncology (Northwood, London, England) 35, no. 3 (2018): 32. https://doi.org/10.1007/s12032-018-1087-6.

MLA (9th ed.) Citation

H, Fuchs, et al. "Modified Biweekly Cisplatin, Docetaxel Plus Cetuximab (TPEx) as First-line Treatment for Patients with Recurrent/metastatic Head and Neck Cancer." Medical Oncology (Northwood, London, England), vol. 35, no. 3, 2018, p. 32, https://doi.org/10.1007/s12032-018-1087-6.